<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Doxepin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01142</strong>&#160; (APRD00398)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Doxepin hydrochloride is a dibenzoxepin-derivative tricyclic antidepressant (<span class="caps">TCA</span>). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, doxepin does not affect mood or arousal, but may cause sedation. In depressed individuals, doxepin exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as doxepin and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &#946;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &#945;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Doxepin has less sedative and anticholinergic effects than amitriptyline. See toxicity section below for a complete listing of side effects. Doxepin may be used to treat depression and insomnia. Unlabeled indications include chronic and neuropathic pain, and anxiety. Doxepin may also be used as a second line agent to treat idiopathic urticaria.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01142/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01142/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01142.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01142.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01142.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01142.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01142.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01142">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Doxepin Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000059/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000059/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: MHNSPTUQQIYJOT-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 315.138992038</li>
              <li>Average Mass: 315.837</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000059">DBSALT000059</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adapin</td><td>PennwaIt</td></tr><tr><td>Aponal</td><td>Pfizer</td></tr><tr><td>Curatin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Doxepine</td><td>Shou Chan</td></tr><tr><td>Prudoxin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quitaxon</td><td>Lexphar</td></tr><tr><td>Silenor </td><td>Somaxon Pharmaceuticals, Inc. </td></tr><tr><td>Sinequan</td><td>Pfizer</td></tr><tr><td>Zonalon</td><td>Fougera</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adrenergic-uptake-inhibitors">Adrenergic Uptake Inhibitors</a></li>
<li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>1668-19-5</td></tr><tr><th>Weight</th><td>Average: 279.3761<br>Monoisotopic: 279.162314299</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>21</sub>NO</td></tr><tr><th>InChI Key</th><td>ODQWQRRAPPTVAG-BOPFTXTBSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">dimethyl(3-{9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}propyl)amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzoxepines</td></tr><tr><th>Subclass</th><td>Dibenzoxepines</td></tr><tr><th>Direct parent</th><td>Dibenzoxepines</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Benzene and Substituted Derivatives; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; benzene; tertiary amine; polyamine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Doxepin is used for the treatment of depression and/or anxiety. It can also be used for chronic urticaria and in the management of pain. </td></tr><tr><th>Pharmacodynamics</th><td>Doxepin, a tricyclic antidepressant of the dibenzoxepin type, is used to treat depression and anxiety and, topically, pruritus associated with eczema. Doxepin has substantial anticholinergic and sedative effects. The E (trans)-isomer is more active as a serotonin reuptake inhibitor while the Z-isomer acts as a sedative. </td></tr><tr><th>Mechanism of action</th><td>The mechanism of action of doxepin is not completely understood. It is thought that like amitriptyline, doxepin enhances the actions of norepinephrine and serotonin by blocking their reuptake at the neuronal membrane. However, doxepin weakly inhibits the reuptake of dopamine. Doxepin may also act on histamine H<sub>1</sub>-receptors, resulting in sedative effects, and &#946;-adrenergic receptors. It is also an antagonist of 5-hydroxytryptamine (serotonin) receptors, alpha-1 adrenergic receptor, and muscarinic cholinergic receptors. </td></tr><tr><th>Absorption</th><td>Well-absorbed from the GI tract. Peak plasma concentrations occur within 2 hours of oral administration. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Doxepin and desmethyldoxepin is 80% protein bound. It is also a lipophillic drug and is capable of crossing the blood-brain-barrier. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Extensively metabolized in the liver via the same pathways as other TCAs. <i>N</i>-demethylation produces an active metabolite, <i>N</i>-desmethyldoxepin. CYP2D6 specifically hydroxylates the E-isomer. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00315">N-desmethyldoxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/316">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00844">Doxepin N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/865">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00873">(E)-2-hydroxydoxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/894">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00875">(Z)-N-desmethyldoxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/896">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00876">(E)-N-desmethyldoxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/897">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00877">Doxepin-N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/898">Details</a></td></tr><tr><td>Doxepin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00878">(E)-2-O-glucuronyldoxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/899">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00315">N-desmethyldoxepin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00834">Didesmethyl doxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1113">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00844">Doxepin N-oxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00845">Doxepin N-oxide glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1114">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00873">(E)-2-hydroxydoxepin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00881">Hydroxydoxepin glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1115">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00315">N-desmethyldoxepin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00872">Hydroxydesmethyl doxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1116">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00873">(E)-2-hydroxydoxepin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00872">Hydroxydesmethyl doxepin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1117">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00872">Hydroxydesmethyl doxepin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00879">Hydroxydesmethyl doxepin glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1118">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>6 - 24.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=26 (mg/kg) (in mice, iv); LD<sub>50</sub>=16 (mg/kg) (in rats, iv); Cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. 
Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. 
Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia. 
</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Doxepin Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00641?highlight%5Bcompounds%5D%5B%5D=DB01142&amp;highlight%5Bproteins%5D%5B%5D=DB01142">SMP00641</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9931</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8108</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8147</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8147</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8214</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7883</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7846</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7475</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.917</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6362</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8322
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8461
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.2478 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5346
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6959
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Clonmel healthcare ltd</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>New river pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Purepac pharmaceutical co</li>
<li>Quantum pharmics ltd</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li>
<li>Pharmaceutical assoc inc</li>
<li>Silarx pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Nycomed us inc</li>
<li>Pfizer Inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Bioglan Pharmaceuticals Co.</li>
<li>Coupler Enterprises Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.dptlabs.com">DPT Laboratories Ltd.</a></li>
<li><a href="http://www.healthpoint.com">Healthpoint Ltd.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Lederle Arzneimittel Cyanamid GmbH</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaderm.com">Pharmaderm</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.silarx.com">Silarx Pharmaceuticals</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg</td></tr><tr><td>Concentrate</td><td>Oral</td><td>10 mg/mL</td></tr><tr><td>Cream</td><td>Topical</td><td>5%</td></tr><tr><td>Tablet</td><td>Oral</td><td>3 mg, 6 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Zonalon 5% Cream 45 gm Tube</td><td>190.13USD</td><td>tube</td></tr><tr><td>Zonalon 5% Cream 30 gm Tube</td><td>144.29USD</td><td>tube</td></tr><tr><td>Doxepin hcl powder</td><td>8.88USD</td><td>g</td></tr><tr><td>Doxepin 150 mg capsule</td><td>3.33USD</td><td>capsule</td></tr><tr><td>Prudoxin 5% cream</td><td>3.05USD</td><td>g</td></tr><tr><td>Sinequan 100 mg Capsule</td><td>1.22USD</td><td>capsule</td></tr><tr><td>Novo-Doxepin 150 mg Capsule</td><td>1.18USD</td><td>capsule</td></tr><tr><td>Sinequan 75 mg Capsule</td><td>0.93USD</td><td>capsule</td></tr><tr><td>Zonalon 5% cream</td><td>0.89USD</td><td>g</td></tr><tr><td>Doxepin HCl 150 mg capsule</td><td>0.87USD</td><td>capsule</td></tr><tr><td>Apo-Doxepin 100 mg Capsule</td><td>0.68USD</td><td>capsule</td></tr><tr><td>Novo-Doxepin 100 mg Capsule</td><td>0.68USD</td><td>capsule</td></tr><tr><td>Sinequan 50 mg Capsule</td><td>0.64USD</td><td>capsule</td></tr><tr><td>Doxepin 50 mg capsule</td><td>0.57USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 100 mg capsule</td><td>0.56USD</td><td>capsule</td></tr><tr><td>Novo-Doxepin 75 mg Capsule</td><td>0.52USD</td><td>capsule</td></tr><tr><td>Apo-Doxepin 75 mg Capsule</td><td>0.52USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 75 mg capsule</td><td>0.43USD</td><td>capsule</td></tr><tr><td>Apo-Doxepin 50 mg Capsule</td><td>0.36USD</td><td>capsule</td></tr><tr><td>Novo-Doxepin 50 mg Capsule</td><td>0.36USD</td><td>capsule</td></tr><tr><td>Sinequan 25 mg Capsule</td><td>0.35USD</td><td>capsule</td></tr><tr><td>Doxepin 10 mg capsule</td><td>0.32USD</td><td>capsule</td></tr><tr><td>Sinequan 10 mg Capsule</td><td>0.28USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 50 mg capsule</td><td>0.25USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 25 mg capsule</td><td>0.23USD</td><td>capsule</td></tr><tr><td>Doxepin 75 mg capsule</td><td>0.21USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 10 mg capsule</td><td>0.21USD</td><td>capsule</td></tr><tr><td>Apo-Doxepin 10 mg Capsule</td><td>0.2USD</td><td>capsule</td></tr><tr><td>Apo-Doxepin 25 mg Capsule</td><td>0.19USD</td><td>capsule</td></tr><tr><td>Novo-Doxepin 25 mg Capsule</td><td>0.19USD</td><td>capsule</td></tr><tr><td>Doxepin 25 mg capsule</td><td>0.18USD</td><td>capsule</td></tr><tr><td>Doxepin 100 mg capsule</td><td>0.14USD</td><td>capsule</td></tr><tr><td>Doxepin HCl 10 mg/ml Concentrate</td><td>0.13USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>&lt; 25 &#176;C</td><td>PhysProp</td></tr><tr><td>boiling point</td><td>265 &#176;C at 2.00E-01 mm Hg</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>31.6 mg/L (at 25 &#176;C)</td><td>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</td></tr><tr><td>logP</td><td>4.29</td><td>SANGSTER (1994)</td></tr><tr><td>logS</td><td>-3.4</td><td>ADME Research, USCD</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.19e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.08</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.84</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.9</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>12.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>98.24</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>32.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox, &#8220;<span class="caps">LOW</span>-<span class="caps">DOSE</span> <span class="caps">DOXEPIN</span> <span class="caps">FORMULATIONS</span> <span class="caps">AND</span> <span class="caps">METHODS</span> OF <span class="caps">MAKING</span> <span class="caps">AND</span> <span class="caps">USING</span> <span class="caps">THE</span> <span class="caps">SAME</span>.&#8221; U.S. Patent US20090074862, issued March 19, 2009.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20090074862&amp;tbm=pts" target="_blank">US20090074862 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Virtanen R, Iisalo E, Irjala K: Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh). 1982 Aug;51(2):159-64. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7113722">Pubmed</a></li>
	<li>Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7293791">Pubmed</a></li>
	<li>Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7293791">Pubmed</a></li>
	<li>Negro-Alvarez JM, Carreno-Rojo A, Funes-Vera E, Garcia-Canovas A, Abellan-Aleman AF, Rubio del Barrio R: Pharmacologic therapy for urticaria. Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):36-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9111875">Pubmed</a></li>
	<li>Sansone RA, Sansone LA: Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008 Dec;5(12):16-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19724772">Pubmed</a></li>
	<li>Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12360109">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D07875" target="_blank">D07875 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C06971" target="_blank">C06971 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=4710" target="_blank">4710 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1628227" target="_blank">CHEMBL1628227 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000177" target="_blank">DAP000177 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449409" target="_blank">PA449409 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=1225" target="_blank">1225 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1225" target="_blank">1225 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=1913425" target="_blank">1913425 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/doxepin.htm" target="_blank">http://www.rxlist.com/cgi/generic/doxepin.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/doxepin-capsules.html" target="_blank">http://www.drugs.com/cdi/doxepin-capsules.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Doxepin" target="_blank">Doxepin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N06AA12<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06A#N06A">N06A &#8212; ANTIDEPRESSANTS</a></li><li><a href="/atc/N06AA#N06AA">N06AA &#8212; Non-selective monoamine reuptake inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>84:08.00</li>
<li>28:16.04.28</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01142.pdf?1265922807">show</a>(588 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01142.pdf?1265922745">show</a>(73.4 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00488">Altretamine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the effect of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00575">Clonidine</a></td><td>The tricyclic antidepressant, doxepin, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin.</td></tr><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine.</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine.</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedra.</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedrine.</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine.</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of fenoterol.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>The tricyclic antidepressant, doxepin, decreases the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of isoproterenol.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol.</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine.</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of norepinephrine.</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine.</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine.</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pirbuterol.</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of procaterol.</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pseudoephedrine.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin.</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of salbutamol.</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxepin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Doxepin. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Doxepin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of terbutaline.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00730">Thiabendazole</a></td><td>The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excessive quantities of coffee or tea (caffeine).</li>
<li>Avoid St.John's Wort.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>